Image Place holder

Jameel Muzaffar, MD

Specialty: Medical Oncology
Program: Head and Neck Oncology

Overview

Cancer Focus: Head and Neck Cancer

Dr. Jameel Muzaffar is an Assistant Member in the Moffitt Cancer Center Department of Head and Neck-Endocrine Oncology. Dr. Muzaffar received his MBBS degree from Maulana Azad Medical College in India. He completed an Internal Medicine Residency at St. Mary’s Health Service in St. Louis, MO. Dr. Muzaffar was employed at the Myeloma Institute of Research and Therapy at the University of Arkansas for Medical Sciences at the rank of Assistant Professor. He also served as the Physician Director of Infusion 4, Winthrop Rockefeller Cancer Institute. Dr. Muzaffar was previously employed at Moffitt Cancer Center in the Department of Internal Medicine/Internal & Hospital Medicine Program. He recently completed a Clinical Fellowship in Hematology-Oncology at the University of Florida, Gainesville. Dr. Muzaffar’s clinical interest includes taking care of patients with advanced stage head and neck cancers and endocrine cancers. His clinical focus is developing a multi-disciplinary care approach involving radiation oncology, surgery, medical oncology, nutrition, speech pathology, pharmacy, palliative care, and social work to provide comprehensive care to head and neck cancer and thyroid cancer patients. His research interest is in developing new therapy options for patients with advanced stage cancers and to bring innovative trials for the benefit of these patients. 


Education & Training

Fellowship:

  • University of Florida at Gainesville - Hematology Oncology

Residency:

  • Maulana Azad Medical college - Internal Medicine
  • St. Mary's Health Center - Internal Medicine

Medical School:

  • Maulana Azad Medical college - MBBS
Participating Trials

CLINICAL TRIAL 20274
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Radiotherapy (); cisplatin ()
Open

CLINICAL TRIAL 20132
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Condition: Multiple
Intervention: FLX475 (); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 21150
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients with Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 21077
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Condition: Head & Neck
Intervention: 5-fluorouracil (); ALX148 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); carboplatin (); cisplatin ()
Open

CLINICAL TRIAL 21078
A Phase 2 Study of ALX148 in Combination with Pembrolizumab and chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Condition: Head & Neck
Intervention: 5-fluorouracil (); ALX148 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); carboplatin (); cisplatin ()
Open

CLINICAL TRIAL 21641
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Condition: Head & Neck
Intervention: BCA101 (); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 21282
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: BKM120 (Buparlisib); Buparlisib (); Taxol (paclitaxel); paclitaxel ()
Open

CLINICAL TRIAL 20285
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in P53 Wild-Type Salivary Gland Carcinoma
Condition: Head & Neck
Intervention: APG-115 ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Oswald LB, Arredondo B, Geiss C, Vigoureux TFD, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HSL, Kirtane K. Considerations for developing supportive care interventions for survivors of head and neck cancer: A qualitative study. Psychooncology. 2022 Sep.31(9):1519-1526. Pubmedid: 35726386. Pmcid: PMC9452460.
  • Kirtane K, Geiss C, Arredondo B, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HSL, Oswald LB. "I have cancer during COVID; that's a special category": a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic. Support Care Cancer. 2022 May.30(5):4337-4344. Pubmedid: 35091844. Pmcid: PMC8799415.
  • Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Jun.28(11):2329-2338. Pubmedid: 35344035. Pmcid: PMC9167762.
  • Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35676062. Pmcid: PMC9185557.
  • Crowder SL, Hoogland AI, Welniak TL, LaFranchise EA, Carpenter KM, Li D, Rotroff DM, Mariam A, Pierce CM, Fischer SM, Kinney AY, Dong-Binh Tran T, Rastegari F, Berry DL, Extermann M, Kim RD, Tometich DB, Figueiredo JC, Muzaffar J, Bari S, Turner K, Weinstock GM, Jim HSL. Metagenomics and chemotherapy-induced nausea: A roadmap for future research. Cancer. 2022 Feb.128(3):461-470. Pubmedid: 34643945. Pmcid: PMC8776572.
  • Bari S, Muzaffar J, Eroglu Z. Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?. Ther Adv Med Oncol. 2022 Apr.14. Pubmedid: 35478991. Pmcid: PMC9036333.
  • Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Bari S, Chineke I, Darwin A, Umar A, Jim H, Muzaffar J, Kucuk O. Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. Integr Cancer Ther. 2021 Jan.20. Pubmedid: 34923869. Pmcid: PMC8724982.
  • Abou-Foul AK, Muzaffar J, Diakos E, Best JE, Momtahan N, Jayaram S. Correlation Between Thyroid Fine Needle Aspiration Cytology and Postoperative Histology: A 10-Year Single-Centre Experience. Cureus. 2021 Apr.13(4):e14504. Pubmedid: 34007757. Pmcid: PMC8123937.
  • Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. J Oncol. 2019 Jan.2019:2989048. Pubmedid: 31275380. Pmcid: PMC6582789.
  • Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS. Corrigendum to "Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features". Case Rep Hematol. 2019 Aug.2019:1548610. Pubmedid: 31467738. Pmcid: PMC6701371.
  • Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Corrigendum to "Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer". J Oncol. 2019 Aug.2019:7921582. Pubmedid: 31531021. Pmcid: PMC6719266.
  • Nguyen TC, Bajwa R, Bari S, Ali A, Paul Skelton W, Federico RA, Bishnoi R, Wray JW, Zlotecki RA, Dang LH, Muzaffar J. Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. Oxf Med Case Reports. 2018 Jan.2018(1):omx078. Pubmedid: 29340160. Pmcid: PMC5761507.
  • Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. Case Rep Hematol. 2018 Feb.2018:9052314. Pubmedid: 29785311. Pmcid: PMC5896379.
  • Best J, Muzaffar J, Mitchell-Innes A. Quality of information available via the internet for patients with head and neck cancer: are we improving?. Eur Arch Otorhinolaryngol. 2015 Nov.272(11):3499-3505. Pubmedid: 25370600.
  • Hardman J, Muzaffar J, Nankivell P, Coulson C. Tympanoplasty for Chronic Tympanic Membrane Perforation in Children: Systematic Review and Meta-analysis. Otol Neurotol. 2015 Jun.36(5):796-804. Pubmedid: 25899552.
  • Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D, Barlogie B, Usmani SZ. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Jun.14(3):211-214. Pubmedid: 24373936.
  • Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun.121(23):4753-4757. Pubmedid: 23603914. Pmcid: PMC3674673.
  • Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol. 2013 Dec.130(3):146-149. Pubmedid: 23689541.
  • Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013 Aug.13(4):502-506. Pubmedid: 23747080.
  • Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013 Aug.15(4):354-360. Pubmedid: 23578205.
  • Abdallah AO, Westfall C, Brown H, Muzaffar J, Atrash S, Nair B. Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis. Am J Case Rep. 2013 Apr.13:102-105. Pubmedid: 23569501. Pmcid: PMC3615912.
  • Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. Clin Lymphoma Myeloma Leuk. 2013 Apr.13(2):171-174. Pubmedid: 23313066.
  • Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012 Jan.95(1):102-106. Pubmedid: 22170228.
  • Pillai U, Muzaffar J, Uppaluri C. Peripheral arterial thrombosis with presence of anti-centromere antibodies and polycythemia vera. Mo Med. 2009 Sep.106(5):369-372. Pubmedid: 19902720.
  • Pillai U, Muzaffar J, Sen S, Yancey A. Grapefruit juice and verapamil: a toxic cocktail. South Med J. 2009 Mar.102(3):308-309. Pubmedid: 19204629.
  • Singh P, Singla M, Gupta N, Muzaffar J, Babu R, Sakhuja P, Aggarwal A, Kar P. Inflammatory pseudotumour of the liver: a diagnostic dilemma. Trop Gastroenterol. 2008 Jan.29(1):40-43. Pubmedid: 18564668.
  • Muzaffar J, Venkata Krishnan P, Gupta N, Kar P. Dengue encephalitis: why we need to identify this entity in a dengue-prone region. Singapore Med J. 2006 Nov.47(11):975-977. Pubmedid: 17075667.
  • Gupta N, Krishnan PV, Muzaffar J, Arora A, Anuradha S, Gondal R, Agarwal A, Kar P. Cystic ductal adenocarcinoma of pancreas: an unusual variant. Trop Gastroenterol. 2006 Jul.27(3):131-133. Pubmedid: 17310557.
  • Muzaffar J, Madan K, Sharma MP, Kar P. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Digest Dis Sci. 2006 Dec.51(12):2270-2273. Pubmedid: 17103040.

Grants

Title: Immunotherapy in head and neck cancer - Role of gut microbiome/metabolome in racial disparity.
Sponsor: Moffitt Cancer Center
PI: Muzaffar, J.
Title: Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients with Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Sponsor: Bristol Myers Squibb Foundation
PI: Muzaffar, J.
Title: Gut Microbiome/metabolome as a Predictor and Modulator of Response to Immunotherapy in Head and Neck Cancer
Sponsor: Ocala Royal Dames
PI: Muzaffar, J.
Title: Gut microbiome/metabolome as a predictor and modulator of response to immunotherapy in head and neck cancer
Sponsor: Moffitt Cancer Center
PI: Muzaffar, J.

Patient Comments
Overall Satisfaction
4.9

103 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments